Targeting HIV reservoir by DART molecules that recruit T cells to HIV Env expressing cells: comparison of HIV arms derived from broadly reactive neutralizing or non-neutralizing anti-Env antibodies
Year: 2015
Type: article
Abstract: Background: HIV reservoirs and production of viral antigens are not eliminated in HIV-infected individuals treated with combination antiretroviral therapy (cART) and novel therapeutic strategies are needed.Dual-Affinity Re-Targeting (DART) molecules exhibit a distinct mechanism of action via binding the viral envelope (Env) antigen on the surface of HIV-infected cells and simultaneously engaging CD3 on cytotoxic T lymphocytes (CTLs).Methods: HIVxCD3 DART proteins were made in which HIV arms were derived from diverse broadly reactive Env-specific antibodies with (bnAbs) or without (non-nAbs) virus neutralizing activity.They were evaluated for antigen binding by ELISA, cell surface antigen binding by flow cytometry, CD8-dependent killing of HIV-infected Env-expressing target cells, and effect on virus propagation.Results: HIVxCD3 DART proteins derived from two bnAbs (PGT121, PGT145) and two non-nAbs (A32, 7B2), but not from two other bnAbs (VRC01, 10E8), mediated potent CTL-dependent killing of quiescent primary CD4 T cells infected with diverse HIV isolates.Similar redirected CTL activity was also observed with DART molecules structurally modified for in vivo half-life extension.In an ex vivo model using cells isolated from HIV-infected individuals on suppressive cART, combinations of the most potent DART molecules reduced HIV expression both in quiescent and activated peripheral blood mononuclear cell cultures.Importantly, DART molecules did not induce cell-to-cell virus spread in resting or activated CD4 T cell cultures and ones with HIV arms derived from bnAbs retained virus neutralizing activity.Conclusion: HIVxCD3 DART molecules potently and selectively mediate the killing of HIV-infected cells.Furthermore, they perturb resting and activated viral reservoirs in cells isolated from individuals on antiviral therapy.The data provide support for further pursuit of HIVxCD3 DART molecules as a promising therapeutic strategy for targeting HIV reservoirs.
Source: Journal of Virus Eradication
Institutions: MacroGenics (United States), Gilead Sciences (United States)
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W3045303091
